|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,036 JPY | +2.50% |
|
+4.03% | +6.79% |
| Apr. 04 | Rohto Pharmaceutical Eyes MGO on Singapore's Eu Yan Sang International for 88 Billion Yen | MT |
| Apr. 04 | Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang -- Update | DJ |
Rohto Pharmaceutical Co.,Ltd. reported earnings results for the full year ended March 31, 2023. For the full year, the company reported sales was JPY 238,664 million. Net income was JPY 26,377 million.
Basic earnings per share from continuing operations was JPY 115.62. Diluted earnings per share from continuing operations was JPY 115.29.
| 1st Jan change | Capi. | |
|---|---|---|
| +6.79% | 4.4B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
ROHTO PHARMACEUTICAL CO.,LTD. 
